Sam is gone for the day and he gave up understanding the changed format..
Where did you graduate my friend?This must be the funniest post of the week. Dividend policy has nothing to do with share price. In fact it is the other way around. Dividends will be based on company profitability and PPS will eventually re-align to business fundamentals, company profitability and dividend policy.
you sound desperate... so I am generous and I will give you a hint. 7 analysts rate CNAT strong buy/buy with 1 year mean target of $13 (and that was before this morning fast track news). Listen to my advice, do not short this stock, and if you have already shorted it, just close it asap..
Cash balance close to $40M. No debt. Fast tracked in NASH Cirrhosis. Safe and effective in all trials so far. Potential cure in a $50B+ market with no approved cure. For all the above the Company and Emricasan are selling for free now
$1.80 is the long term and sustainaible expected dividend per annum. $0.54 is the special dividend on the transaction. This year at the moment we expect $2.34 per share.
Emricasan is being given for free (plus some cash) at these prices since market cap is less than cash on hand and the company has no debt.. Emricasan might address the whole spectrum of Liver diseases in an estimated $50- .$100B potential market where there is no cure/treatment. So far the drug has proven effective and safe. Best for the company to partner with some big pharma, get all the trials funded and share the reward. Only such deal would probably cause a 10 times appreciation in no time. Activity on the stock is either very irrational (computer trading) or this is being done on purpose with the only aim of stealing as many shares as possible. My guess is there is something happening behind the scenes.
Global market is $6B. The only oral safe and effective drug to be approved soon would definitively catch more than 10% of global market. Moreover due to many patients non compliant patients dropping off current drugs (inections nuisance or contamination risks), I would expect global market to increase significantly due to the launch of safe, effective and easy to administer drug. I would not be surpised to see global sales in the USD billions within 2-3 years